Dr. Reddy's Laboratories Launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the US Market
28 July 2022 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the US market approved by the US Food and Drug Administration, the company said.

The Velcade Brand and generic had US sales of approximately USD 1.2bn MAT for the most recent twelve months ending in May 2022 according to Iqva Health.

Dr. Reddy's Bortezomib for Injection is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous or intravenous use.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.